← Back to Search

Cannabinoid

Cannabidiol, pharmaceutically produced with < 5 ppm THC for COVID-19

Phase 2 & 3
Waitlist Available
Research Sponsored by Cardiol Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

This trial is for non-critical patients who were recently hospitalized and tested positive for COVID-19. The patients must have a prior history of cardiovascular disease or significant risk factors for cardiovascular disease. The treatment will last for 28 days.

Eligible Conditions
  • COVID-19
  • Cardiovascular Disease
  • Coronavirus
  • Cardiovascular Risk

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
All-cause mortality
CV complications
Requirement for ICU admission and/or ventilatory support

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cannabidiol, pharmaceutically produced with < 5 ppm THCExperimental Treatment1 Intervention
CardiolRx
Group II: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

Cardiol Therapeutics Inc.Lead Sponsor
2 Previous Clinical Trials
125 Total Patients Enrolled
Dennis McNamara, MDStudy ChairUniversity of Pittsburgh
4 Previous Clinical Trials
798 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research project still enrolling new participants?

"Yes, this trial is recruiting patients according to the latest information on clinicaltrials.gov. The trial was first posted on April 30th, 2021 and was edited most recently on July 21st, 2022. There are presently 7 active sites for this study and a total of 422 patients are needed between them."

Answered by AI

In how many hospitals is this study being conducted?

"There are a total of 7 sites running this study at the moment, with locations in Cutler Bay, Miami and San Antonio. If you live close to any of these centres, it would be ideal to select that one to minimize travel time and effort."

Answered by AI

How many people are being signed up for this clinical trial?

"That is correct. The most recent update on clinicaltrials.gov shows that this trial, which was initially posted on April 30th 2021, is still looking for participants. In total, 422 individuals are needed across 7 different locations."

Answered by AI

Is there extensive research on CBD that has been pharmaceutically sourced with low THC levels?

"Cannabidiol, which has a THC concentration of less than 5 ppm and is pharmaceutically produced, was first studied in 2012. There have been 18359 completed clinical trials since then. As of now, there are 83 live studies being conducted--many of which are based out of Cutler Bay, Texas."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
2021. "Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04615949.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top